natgillin/translations-raw huggingface dataset:
Efavirenz/Emtricitabine/Tenofovir disoproxil Krkas sikkerhed hos børn under 18 år er ikke klarlagt.
The safety and efficacy of efavirenz/emtricitabine/tenofovir disoproxil in children under the age of 18 years have not been established.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krkas farmakokinetik er ikke undersøgt hos patienter med nedsat leverfunktion.
The pharmacokinetics of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka > have not been studied in patients with hepatic impairment.
Hvis behandling med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka seponeres, bør efavirenz' lange halveringstid (se pkt.
If therapy with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is discontinued, consideration should be given to the long half-life of efavirenz (see section 5.2) and long intracellular half-lives of emtricitabine and tenofovir.
- Brugsanvisning for lineal med to skalaer til beregning af kreatininclearance
Instructions on the use of the creatinine clearance slide ruler
3, abnorm tankevirksomhed
3, amnesia convulsions thinking abnormal ataxia
De eksisterende data, antyder, at det kan medføre en reduktion i behandlingsresponsen, når patienter skifter fra en antiretroviral behandling, der er baseret på proteasehæmmere, til efavirenz/emtricitabine/tenofovirdisoproxil, (se pkt.
Currently available data indicate a trend that in patients on a PI-based antiretroviral regimen the switch to efavirenz/emtricitabine/tenofovir disoproxil may lead to a reduction of the response to the therapy (see section 5.1).
Sofosbuvir/velpatasvir og sofosbuvir/velpatasvir/voxilaprevir Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/voxilaprevir frarådes (se pkt.
Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended (see section 4.4 and Table 1).
Metadon/efavirenz (35-100 mg q.d./600 mg q.d.)
Methadone/Efavirenz (35-100 mg q.d./600 mg q.d.)
Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og didanosin frarådes (se pkt.
Co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and didanosine is not recommended (see section
hvis du i øjeblikket tager et eller flere af følgende lægemidler (se også “Brug af anden medicin sammen med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka”): - astemizol eller terfenadin (mod høfeber eller andre allergier) - bepridil (mod hjertesygdom) - cisaprid (mod halsbrand) - elbasvir/grazoprevir (medicin til behandling af hepatitis C) - ergotalkaloider (f.eks. ergotamin, dihydroergotamin, ergonovin og methylergonovin)
if you are currently taking any of the following medicines (see also “Other Medicines and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka”): astemizole or terfenadine (used to treat hay fever or other allergies) - bepridil (used to treat heart disease) - cisapride (used to treat heartburn) - elbasvir/grazoprevir (used to treat hepatitis C) - ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (used to treat migraines and cluster headaches) - midazolam or triazolam (used to help you sleep) - pimozide, imipramine, amitriptyline or clomipramine (used to treat certain mental conditions) - St. John's wort (Hypericum perforatum) (a herbal preparation used for depression and anxiety) - voriconazole (used to treat fungal infections) - flecainide, metoprolol (used to treat irregular heart beat) - certain antibiotics (macrolides, fluoroquinolones, imidazole) - triazole antifungal agents - certain antimalarial agents - methadone (used to treat opiate addiction)
M184V/I
M184V/I K65R K70E TAMs
Hyperkolesterolæmi
Uncommon hypercholesterolaemia hypokalaemia
Artemether: AUC: ↓ 51% Cmax: ↓ 21%
AUC: ↓ 51% Cmax: ↓ 21%
resulterede i signifikant nedsat simeprevir-plasmakoncentration på grund af efavirenz-forårsaget CYP3A-induktion, som kan resultere i manglende terapeutisk virkning af simeprevir.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, resulted in significantly decreased plasma concentrations of simeprevir due to CYP3A induction by efavirenz, which may result in loss of therapeutic effect of simeprevir.
Kontakt lægen eller apotekspersonalet, før du tager Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Talk to your doctor or pharmacist before taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
I forbindelse med en reduceret dosis på 250 mg didanosin administreret samtidig med tenofovirdisoproxil er der blevet rapporteret
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virologic failure within several tested combinations.
Tacrolimus: AUC: ↔ Cmax: ↔ C24t: ↔
Tacrolimus: AUC: ↔ Cmax: ↔ C24h: ↔
Det anbefales, at Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tages på tom mave, da mad kan øge efavirenz-eksponeringen og kan føre til øget bivirkningsfrekvens (se pkt.
It is recommended that Efavirenz/Emtricitabine/Tenofovir disoproxil Krka be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan nedsætte mængden af den krampestillende medicin i blodet.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of the anticonvulsant in your blood.
Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er et fastdosis-kombinationsprodukt, kan efavirenzdosis ikke ændres; voriconazol og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka må derfor ikke administreres samtidigt (se pkt.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is a fixeddose Combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka must not be coadministered.
Monitorering af nyrefunktionen kan være indiceret, især hos patienter med underliggende systemisk sygdom eller nyresygdom, eller hos patienter,
particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sammen med mad kan øge efavirenz-eksponeringen og kan medføre en højere bivirkningsfrekvens (se pkt.
The administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 5.2).
Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er et fast-dosis kombinationsprodukt, kan efavirenzdosis ikke ændres; voriconazol og
Since Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efavirenz/Emtricitabine/Tenofovir disoproxil
Allergiske reaktioner
Skin reactions
Det er vigtigt, at du ikke springer en dosis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka over.
It is important not to miss a dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og didanosin frarådes, da didanosin-eksponeringen øges signifikant efter samtidig administration af tenofovirdisoproxil (se pkt.
Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sløret syn
dizziness headache
Hvis du har glemt at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
If you forget to take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg filmovertrukne tabletter efavirenzum/emtricitabinum/tenofovirum disoproxilum
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets efavirenz/emtricitabine/tenofovir disoproxil
Saquinavir/ritonavir/emtricitabin Interaktion er ikke undersøgt.
Saquinavir/ritonavir/Emtricitabine Interaction not studied.
Atazanavir/ritonavir/emtricitabin Interaktion er ikke undersøgt.
Atazanavir/ritonavir/Emtricitabine Interaction not studied.
3, amnesi
3, catatonia
Du bør ikke tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sammen med nogle af disse lægemidler.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be taken with any of these medicines.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka skal sluges hel sammen med vand.
Swallow Efavirenz/Emtricitabine/Tenofovir disoproxil Krka whole with water.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør ikke gives til patienter med moderat eller svært nedsat nyrefunktion (kreatininclearance <50 ml/min).
Efavirenz/emtricitabine/tenofovir disoproxil is not recommended for patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min).
Dosisjustering af calciumantagonister, når disse administreres samtidigt med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, bør styres af klinisk respons (se produktresuméet for calciumantagonisten).
Dose adjustments of calcium channel blockers when coadministered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
AUC: ↓ 39% (↓ 21 til ↓ 53) Cmax: ↓ 37% (↓ 20 til ↓ 51) Cmin: ↓ 44% (↓ 27 til ↓ 58) (fald i itraconazolkoncentrationerne: CYP3A4-induktion)
Cmax: ↓ 37% (↓ 20 to ↓ 51) Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction)
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og vigabatrin eller gabapentin kan administreres samtidigt uden dosisjustering.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and vigabatrin or gabapentin can be coadministered without dose adjustment.
Brug af anden medicin sammen med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Adverse reactions associated with the use of efavirenz/emtricitabine/tenofovir disoproxil
Hvis du holder op med at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
If you stop taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Saquinavir/ritonavir/tenofovirdisop roxil
Saquinavir/ritonavir/Tenofovir disoproxil
Pakningsstørrelser: Fås i pakninger, der indeholder 30 filmovertrukne tabletter og 90 (3 flasker med 30) filmovertrukne tabletter.
Pack sizes: 30 film coated tablets (1x30) and 90 film-coated tablets (3x30).
Leversvigt
nausea
Mitokondriel dysfunktion bør overvejes hos alle børn med svære kliniske symptomer af ukendt ætiologi, især neurologiske symptomer, der har været eksponeret for nukleosid-/nukleotid-analoger in utero.
These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particulary neurologic findings, These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.
Der er kun utilstrækkelige data til doseringsanbefaling for indinavir, når dette doseres sammen med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Insufficient data are available to make a dosing recommendation for indinavir when dosed with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Justering af buprenorphin-dosis er muligvis ikke nødvendig, når det administreres samtidigt med Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Dose adjustment of warfarin or acenocoumarol may be required when co-administered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
AUC: ↓ 34% (↓ 41 til ↓ 25) Cmax: ↓ 34% (↓ 41 til ↑ 25) Cmin: ↓ 34% (↓ 43 til ↑ 24)
AUC: ↓ 34% (↓ 41 to ↓ 25) Cmax: ↓ 34% (↓ 41 to ↑ 25)
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør ikke anvendes til patienter med moderat eller svært nedsat nyrefunktion (kreatininclearance < 50 ml/min).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended for patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min).
Emtricitabin: AUC: ↔ Cmax: ↔ C24t: ↔
Emtricitabine: AUC: ↔ Cmax: ↔ C24h: ↔
Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan forårsage nyreskader, anbefales monitorering af nyrefunktionen (se pkt.
As Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may cause renal damage, monitoring of renal function is recommended (see sections 4.4 and 4.8 Summary of the safety profile).
Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og sofosbuvir/velpatasvir eller sofosbuvir/velpatasvir/ voxilaprevir frarådes (se pkt.
Co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka with sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is not recommended (see section 4.4).
Værdierne for Test og Reference er gennemsnitlige (% variationskoefficient) GMR: Ratio af middelværdi fundet ved geometriske mindste kvadraters metode, CI=konfidensinterval
GMR=geometric least-squares mean ratio, CI=confidence interval
Kalktab fra knoglerne (med knoglesmerter, som nogle gange resulterer i knoglebrud), som kan forekomme på grund af beskadigelse af de tubulære celler i nyrerne Fedtlever
Your doctor may do blood tests to see if your kidneys are working properly softening of the bones (with bone pain and sometimes resulting in fractures) which may occur due to damage to the kidney tubule cells fatty liver
Du må ikke amme under behandling med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Do not breast-feed during treatment with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, bør justering af diltiazem-dosis styres af klinisk respons (se produktresumé for diltiazem).
Dose adjustments of diltiazem when coadministered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be guided by clinical response (refer to the Summary of Product Characteristics for diltiazem).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og sofosbuvir kan administreres samtidigt uden dosisjustering
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and sofosbuvir can be coadministered without dose adjustment
Tidligere NNRTIbaseret behandling (N=104)
(N=104)
Patienter som samtidigt er inficerede med hiv+HBV eller hiv+HCV:
HIV/HBV or HCV co-infected patients
ANTIEPILEPTIKA Carbamazepin/efavirenz (400 mg q.d./600 mg q.d.)
ANTICONVULSANTS Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
Barrierekontraception bør altid anvendes sammen med andre kontraceptiva (f.eks. orale eller andre hormonkontraceptiva, se pkt.
Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krkas sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt (se pkt.
The safety and efficacy of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka in children under the age of 18 years have not been established (see section 5.2).
Knogler, led, muskler og bindevæv: Meget almindelig
Musculoskeletal and connective tissue disorders: Very common elevated creatine kinase
4, nefrogen diabetes insipidus
(including acute interstitial nephritis) nephrogenic diabetes insipidus
Snurrende eller gyngende fornemmelse (svimmelhed), piben, ringen eller anden vedblivende støj i ørerne
breakdown of muscle, muscle pain or weakness anaemia (low red blood cell count) a feeling of spinning or tilting (vertigo), whistling, ringing or other persistent noise in the ears blurred vision chills breast enlargement in males decreased sexual drive flushing dry mouth increased appetite
Knogleeffekter
Bone effects
Tag ikke Efavirenz/Emtricitabine/Tenofovir disoproxil Krka hvis du er allergisk over for efavirenz, emtricitabin, tenofovir, tenofovirdisoproxil eller et af de øvrige indholdsstoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (angivet i punkt 6).
if you are allergic to efavirenz, emtricitabine, tenofovir disoproxil or any of the other ingredients of this medicine (listed in section 6).
Mundtørhed
Antifungals
Hvis du holder op med at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, kan din læge anbefale, at du genoptager behandling for hepatitis B. Du kan have behov for blodprøver efter 4 måneder for at tjekke hvor godt din lever fungerer.
If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is stopped your doctor may recommend that you resume hepatitis B treatment.
Samtidig administration frarådes
Concomitant use not recommended
Efavirenz/emtricitabin/tenofovirdisoproxil bør administreres med forsigtighed til patienter med let nedsat leverfunktion (se pkt.
Efavirenz/emtricitabine/tenofovir disoproxil should be administered with caution to patients with mild hepatic impairment (see sections 4.3 and 4.4).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (efavirenz 600 mg, emtricitabin 200 mg, tenofovirdisoproxil 245 mg)
Recommendation concerning co-administration with Efavirenz/Emtricitabine/Tenof ovir disoproxil Krka (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg)
3, ataksi unormal koordination agitation
3, affect lability confusional state aggression
Dal-plasmakoncentrationen af boceprevir blev reduceret, når det blev administreret sammen med efavirenz, et aktivt stof i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Plasma trough concentrations of boceprevir were decreased when administered with efavirenz, a component of
Mavesmerter fremkaldt af betændelse i bugspytkirtlen Glemsomhed, forvirring, krampeanfald, usammenhængende tale, rysten (tremor) Gulfarvning af hud eller øjne, kløe eller mavesmerter fremkaldt af betændelse i leveren Beskadigelse af de tubulære celler i nyrerne
allergic reactions disturbances of coordination and balance feeling worried or depressed difficulty sleeping, abnormal dreams, difficulty concentrating, drowsiness pain, stomach pain problems with digestion resulting in discomfort after meals, feeling bloated, wind (flatulence) loss of appetite tiredness itching changes in skin colour including darkening of the skin in patches often starting on hands and soles of feet
Metadon: AUC: ↔ Cmax: ↔ Cmin: ↔
Methadone: AUC: ↔ Cmax: ↔ Cmin: ↔
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og paroxetin kan administreres uden dosisjustering.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and paroxetine can be co-administered without dose adjustment.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og fluoxetin kan administreres uden dosisjustering.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and fluoxetine can be co-administered without dose adjustment.
MINDSTEKRAV TIL MÆRKNING PÅ DEN INDRE EMBALLAGE
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
Lopinavir/ritonavir/emtricitabin Interaktion er ikke undersøgt.
Lopinavir/ritonavir/Emtricitabine Interaction not studied.
Når Efavirenz/Emtricitabine/Tenofovir disoproxil Krka administreres sammen med et plasmakoncentrationer, phenobarbital og andre krampestillende lægemidler, som er substrater for CYP-isozymer, er mulig med efavirenz.
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP isozymes with efavirenz.
Carbamazepin/ tenofovirdisoproxil Interaktion er ikke undersøgt.
Rosuvastatin/Tenofovir disoproxil Interaction not studied.
Diarré, opkastning, kvalme
Common fatigue pain, asthenia
Samtidig administration af lopinavir/ritonavir og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka frarådes.
Coadministration of lopinavir/ritonavir and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is not recommended.
Hvis en patient glemmer at tage en dosis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i mindre end 12 timer efter tidspunktet, hvor patienten normalt tager dosen, skal patienten tage
If a patient misses a dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka within 12 hours of the time it is usually taken, the patient should take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka as soon as possible and resume the normal dosing schedule.
Det skal du vide, før du begynder at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Sådan skal du tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Bivirkninger
What Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is and what it is used for What you need to know before you take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka How to take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Possible side effects
GMR
IJ
AUC: ↓ 52% (↓ 33 til ↓ 66) Cmax: ↓ 45% (↓ 25 til ↓ 59) (CYP3A4-induktion)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er kontraindiceret hos patienter med svært nedsat leverfunktion (se pkt.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is contraindicated in patients with severe hepatic impairment (see section 4.3) and not recommended in patients with moderate hepatic impairment.
Nedsat sexlyst
Hepatic impairment
- At patienterne bør have deres nyrefunktion ved baseline vurderet før behandling med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka initieres - Vigtigheden af regelmæssig monitorering af nyrefunktionen i løbet af behandling med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka - Anbefalet skema for monitorering af nyrefunktion, med hensyntagen til tilstedeværelsen eller fraværet af yderligere risikofaktorer for nedsat nyrefunktion - Hvis serumphosphat er < 1,5 mg/dl eller kreatininclearance reduceres til < 50 ml/min under behandlingen, skal nyrefunktionen revurderes inden for en uge.
That patients should have their baseline renal function assessed prior to initiating Efavirenz/Emtricitabine /Tenofovir disoproxil Krka therapy The importance of regular monitoring of renal function during Efavirenz/Emtricitabine /Tenofovir disoproxil Krka therapy
Samtidig administration af atazanavir/ritonavir og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka frarådes.
Co-administration of atazanavir/ritonavir and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka a is not recommended.
Fosamprenavir/ritonavir/tenofovird isoproxil
Fosamprenavir/ritonavir/Tenofovir disoproxil
AUC: ↑ 34% (↑ 18 til ↑ 53) Cmax: ↑ 49% (↑ 32 til ↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69)
Opbevares utilgængeligt for børn.
Insufficient safety data are available for children below 18 years of age.
Grundet ligheden mellem lamivudin og emtricitabin, en Efavirenz/Emtricitabine/Tenofovir disoproxil Krkakomponent, bør Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ikke gives samtidigt med lamivudin (se pkt.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should not be administered concomitantly with lamivudine (see section 4.4).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og raltegravir kan administreres samtidigt uden dosisjustering.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and raltegravir can be co-administered without dose adjustment.
Darunavir/ritonavir/emtricitabin Interaktion er ikke undersøgt.
Darunavir/ritonavir/Emtricitabine Interaction not studied.
Efavirenz-koncentrationen kan stige, når perikon seponeres.
Efavirenz levels may increase on stopping St. John's wort.
Rabdomyolyse muskelsvækkelse
Uncommon rhabdomyolysis muscular weakness
I
Since
Kombination af emtricitabin og tenofovirdisoproxil:
Combination of emtricitabine and tenofovir disoproxil
Højere tenofovirkoncentrationer kan forstærke tenofovir-associerede bivirkninger inklusive nyrelidelser.
potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders.
Samtidig administration af saquinavir/ritonavir og Efavirenz/Emtricitabine/Tenofovir disoproxil Krka frarådes.
saquinavir/ritonavir and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is not recommended.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og rosuvastatin kan administreres samtidigt uden dosisjustering.
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and rosuvastatin can be coadministered without dose adjustment.